1. Home
  2. CRVS vs RNP Comparison

CRVS vs RNP Comparison

Compare CRVS & RNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$15.98

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Cohen & Steers REIT and Preferred and Income Fund Inc.

RNP

Cohen & Steers REIT and Preferred and Income Fund Inc.

HOLD

Current Price

$21.07

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRVS
RNP
Founded
2014
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
CRVS
RNP
Price
$15.98
$21.07
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$30.17
N/A
AVG Volume (30 Days)
1.2M
82.7K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
7.94%
EPS Growth
48.04
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.38
$19.27
52 Week High
$26.95
$22.99

Technical Indicators

Market Signals
Indicator
CRVS
RNP
Relative Strength Index (RSI) 52.76 55.58
Support Level $14.24 $19.32
Resistance Level $19.21 $21.33
Average True Range (ATR) 1.07 0.25
MACD -0.00 0.02
Stochastic Oscillator 48.94 60.21

Price Performance

Historical Comparison
CRVS
RNP

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.

Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances. The Fund seeks to achieve its objectives through a portfolio of income producing common stock issued by REITs and preferred and other debt securities.

Share on Social Networks: